TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30308287
Drug: Confidence to
Normalized name: miconazole nitrate Topical Cream [Clearly Confident]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confidence to cope with pain without medication
Study: 25364993
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Interoceptive Cues (CBT‐IC)
Study: 23140210
Drug: Adequate initial
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate initial treatment
Study: 19355795
Drug: Salmeterol-fluticasone propionate
Normalized name: fluticasone propionate / salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol-fluticasone propionate combination (SFC)
Study: 15008689
Drug: 42 mg
Normalized name: lithium 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg transdermal nicotine patch for 4 weeks, followed by 8-week dose titration
Study: 15008689
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg transdermal nicotine patch for 4 weeks, followed by 8-week dose titration
Study: 29425304
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline P1NP (>70 ng/mL)
Study: 29425304
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline CTX (>0.299 ng/mL)
Study: 29425304
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline 1‐CTP (>4.2 ng/mL)
Study: 27552061
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g resveratrol
Study: 23890368
Drug: Sub-Tenon injection
Normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon injection of 2.5 ml of 2% lidocaine
Study: 18544974
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) + 2 g of galacto-oligosaccharides (GOS)
Study: 14556322
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone
Study: 9536920
Drug: Vitamin E,
Normalized name: GRx Vitamin E, topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin E, 400 i.u. daily for 8 weeks
Study: 9536920
Drug: L-arginine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (10 mg/min) administration
Study: 7705152
Drug: Nasal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal continuous positive airway pressure therapy (N-CPAP) at a pressure of 10 cm H2O
Study: 2705667
Drug: Chlorpromazine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (0.1 mg/kg, repeated every 15 minutes up to three doses)
Study: 2705667
Drug: Meperidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine with dimenhydrinate (0.4 mg/kg meperidine and 25 mg dimenhydrinate, repeated every 15 minutes up to three doses)
Study: 26790259
Drug: Sea buckthorn
Normalized name: sea buckthorn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sea buckthorn oil treatment once a week
Study: 26790259
Drug: Sea buckthorn
Normalized name: sea buckthorn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sea buckthorn oil treatment
Study: 8290211
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with adjunctive mitomycin C (TMC), n = 35
Study: 3297772
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of current grading system and SAL (serum albumin loss).
Study: 22027646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of micronutrients (Orthomol vital m/f) for three months
Study: 22027646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of micronutrients (Orthomol vital m/f)
Study: 22027646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of micronutrients (Orthomol vital m/f) in male subjects
Study: 18218204
Drug: HNPPV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNPPV group (n=20) with conventional therapy and HNPPV
Study: 18218204
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=20) with conventional therapy only
Study: 14767751
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) only
Study: 11834237
Drug: Sodium cellulose
Normalized name: Sodium cellulose phosphate
DrugBank: Sodium cellulose phosphate (DB06776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cellulose sulfate (CS), 7 consecutive daily doses
Study: 9568181
Drug: Mistletoe lectin
Normalized name: MISTLETOE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe lectin (ML-1) standardized therapy; subcutaneous administration of 0.5-1.0 ng ML-1/kg body weight, twice a week
Study: 8309029
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) niacin at 1500 mg/d and above
Study: 8309029
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) niacin at 1500 mg/d and above
Study: 8309029
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) niacin
Study: 8309029
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) niacin
Study: 29614865
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg/d
Study: 20673994
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) for adolescents with mental health problems; details on dosage and duration not specified.
Study: 8703169
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5000 units, subcutaneously every 12 hours)
Study: 8703169
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin, 30 mg, subcutaneously every 12 hours)
Study: 3890872
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg b.d. for 3 months
Study: 29746232
Drug: Educational booklet
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational booklet about PTSD treatment
Study: 24912463
Drug: Internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioral treatment with motivational support
Study: 24912463
Drug: Internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioral treatment without motivational support
Study: 21771277
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rhPTH(1‐84) at 0.5‐5.0 μg/kg
Study: 21771277
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of rhPTH(1‐84) at 1.0, 2.0, and 4.0 μg/kg
Study: 21771277
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of rhPTH(1‐84) at 2.0 μg/kg once daily for 7 days
Study: 21771277
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of rhPTH(1‐34) at 2.0 μg/kg once daily for 7 days
Study: 21771277
Drug: Post-dosing at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-dosing at 4 hr
Study: 17391172
Drug: Low-dose tri-iodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose tri-iodothyronine (T3)
Study: 9133749
Drug: alprazolam 2
Normalized name: alprazolam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam 2 mg
Study: 9133749
Drug: alprazolam 6
Normalized name: Acetylcarnitine/Choline Bitartrate/Cocoa Extract/Gamma Aminobutyric Acid/Ginkgo Biloba Leaf/Glutamic Acid/Grape Seed Extract/Griffonia Seed Extract/Valerian Root Extract/Whey Protein Hydrolysate;Alprazolam 62.5 MG; 0.5 MG Oral Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam 6 mg
Study: 9133749
Drug: imipramine 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine 225 mg
Study: 7962327
Drug: rhIL-6 infusion
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-6 infusion (150 micrograms)
Study: 7962327
Drug: rhIL-6 administered
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-6 administered sc for 42 consecutive days (150 micrograms)
Study: 26289497
Drug: Sativex (9‐delta‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex (9‐delta‐tetrahydrocannabinol plus cannabidiol) oromucosal spray for 4 weeks (including 2 weeks' titration)
Study: 26289497
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 4 weeks (including 2 weeks' titration)
Study: 19881358
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg/d) added to UDCA
Study: 16640105
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with thymosin-alpha1 (1.6 microg three times per week) and lymphoblastoid interferon (5 MIU three times per week)
Study: 16640105
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with lymphoblastoid interferon (5 MIU three times per week)
Study: 9196087
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 250 microg twice daily for 6 weeks
Study: 6423796
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (10.8 mg/kg/day)
Study: 2139282
Drug: Recombinant yeast-derived
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant yeast-derived hepatitis B vaccine (YDV)
Study: 2139282
Drug: Plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived hepatitis B vaccine (PDV)
Study: 6343878
Drug: Single-dose trimethoprim-sulfametrole
Normalized name: sulfametrole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose trimethoprim-sulfametrole (640 to 3200 mg)
Study: 6343878
Drug: Five-day trimethoprim-sulfametrole
Normalized name: sulfametrole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day trimethoprim-sulfametrole (160 to 800 mg twice daily)
Study: 6343878
Drug: Five-day trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Five-day trimethoprim (200 mg twice daily)
Study: 22113223
Drug: Morphine-bupivacaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-bupivacaine (10 mg morphine and 0.5% bupivacaine)
Study: 22113223
Drug: Tramadol-bupivacaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol-bupivacaine (100 mg tramadol and 0.5% bupivacaine)
Study: 16762960
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose 30 mg
Study: 16762960
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose 100 mg (outflow dialyser line)
Study: 16762960
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose 100 mg (inflow dialyser line)
Study: 15153728
Drug: Unilateral periprostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral periprostatic lidocaine administration
Study: 15153728
Drug: Intravenous synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous synthetic opioid (meperidine or tramadol) administration
Study: 25287762
Drug: Orodispersible L-carnosine
Normalized name: L-Carnosine
DrugBank: Carnosine (DB11695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orodispersible L-carnosine (500 mg OD)
Study: 21194693
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lycopene daily for 8 weeks
Study: 21194693
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg lycopene daily for 8 weeks
Study: 13678475
Drug: Risedronate (RIS)
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate (RIS) 5 mg daily
Study: 6426377
Drug: Self-care medication
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-care medication program
Study: 30767274
Drug: Eculizumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median])
Study: 28163732
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy and dry needling (DN)
Study: 14996106
Drug: Tetracaine gel
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracaine gel (4% w/w)
Study: 14996106
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) gel
Study: 8315224
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine (3 g) plus lysine (3 g) taken twice daily for 14 days
Study: 8315224
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken twice daily for 14 days
Study: 3732582
Drug: Cefoxitin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin administered according to a three-dose, 12 h regimen, first injection given immediately after clamping of the umbilical cord.
Study: 30588573
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal (OAC)
Study: 22060105
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.15 U/kg/die for 18 months)
Study: 10519166
Drug: Cutaneous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cutaneous aspirin (750 mg/day for 10 days)
Study: 10519166
Drug: Cutaneous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cutaneous aspirin
Study: 1674632
Drug: Propranolol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (6 mg)
Study: 3885701
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg chlorthalidone
Study: 7014105
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg xipamide after 100 mg chlorthalidone
Study: 7014105
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg chlorthalidone after 40 mg xipamide
Study: 7014105
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg xipamide and 100 mg chlorthalidone
Study: 31475696
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection of lidocaine in the sphenopalatine ganglion (IL; n=18)
Study: 31475696
Drug: Endoscopic application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic application of topical lidocaine over sphenopalatine ganglion (TL; n=7)
Study: 26452230
Drug: Constraint‐induced movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced movement therapy plus electrical stimulation
Study: 23695232
Drug: Garenoxacin (GRNX)
Normalized name: garenoxacin
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin (GRNX) 400 mg/day for 4 days
Study: 23695232
Drug: SBT/ABPC (sulbactam/ampicillin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/ABPC (sulbactam/ampicillin) 6 g/day for 3 days followed by continuous administration for 4 days
Study: 15296473
Drug: CEE/MPA (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (0.625 mg conjugated equine estrogen plus 5 mg medroxyprogesterone acetate), n=34
Study: 15296473
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg), n=37
Study: 15296473
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg), n=40
Study: 15296473
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no active treatment), n=35
Study: 10924298
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day) and Ticlopidine (2x250 mg/day)
Study: 10924298
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day) and Phenprocoumon (INR 2.0-3.0) with Dipyridamole (3x160 mg/day)
Study: 1576619
Drug: Lactobacillus vaginal
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus vaginal suppositories
Study: 1576619
Drug: Sterilized skim-milk
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterilized skim-milk suppositories
Study: 3691914
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 3% topical minoxidil applied twice daily for 12 months
Study: 3691914
Drug: 2% topical
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% topical minoxidil (Regaine) applied twice daily for 1 year
Study: 31474161
Drug: Intravaginal CO2
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal CO2 laser therapy
Study: 28741622
Drug: CPP-115 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP-115 (80 mg daily for 6, 10, or 14 days)
Study: 23275042
Drug: High-dose octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose octreotide (50 μg/h × 3d + 25 μg/h × 4d)
Study: 23275042
Drug: Low-dose octreotide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose octreotide (25 μg/h × 7d)
Study: 18606428
Drug: Non-Directly Observed
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Directly Observed Treatment (NDOT)
Study: 14650364
Drug: Pranlukast 450
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 450 mg/day for 1 to 2 years
Study: 9014622
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at blood concentrations of 1‐10 micrograms ml‐1
Study: 9014622
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a dose rate of 6.3‐7.8 mg kg‐1 h‐1
Study: 9014622
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a blood concentration of 2.9 micrograms ml‐1
Study: 9014622
Drug: Concentration and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration and dose of propofol
Study: 1563214
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg t.i.d. racemic (R,S)-propranolol
Study: 1563214
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg t.i.d. optically pure (S)-propranolol
Study: 22917599
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention consisting of manual tooth/gum brushing, 0.12% chlorhexidine oral rinse administered twice daily by nurses, and upright feeding positioning at meals.
Study: 8885912
Drug: Oral methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methotrexate, 2.5 mg/day for 5 days
Study: 3927339
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amphetamine sulfate
Study: 27153927
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Hct normalization and exercise training
Study: 24758417
Drug: KRG root
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRG root (3 g)
Study: 20626209
Drug: Ciclosporin (2.5-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (2.5-4 mg/kg/day)
Study: 18494959
Drug: Larval therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larval therapy ('bagged' and 'loose')
Study: 18494959
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (hydrogel)
Study: 7796089
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 50 mg/kg intravenous infusion in saline
Study: 7796089
Drug: Quinine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine plus intravenous saline (Control)
Study: 2109477
Drug: Methohexital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (100 mg induction, 10 mg.min‐1 maintenance)
Study: 2109477
Drug: Midazolam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (15 mg induction, 0.1 mg.min‐1 maintenance) + Flumazenil (0.53 mg mean dose)
Study: 7356888
Drug: Phenelzine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine treatment for 4 weeks
Study: 7356888
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 patients after treatment only)